There may be some "innocent investors" in 401k programs (as someone has said on this board over and over recently), but independent investors sometimes can be blind investors. A small cap company such as $AEGR is indeed no place for blind investors. However, for those doing their homework, and watching this stock daily, AEGR may be a great long-term investment. The company expects revenue of $212M this year. Assuming a 75% profit margin (reasonable for this high priced orphan drug and because I take expenses into account - even for startups), and the typical NASDAQ P/E multiple of 20x, that would put AEGR over a $3B market cap. It, currently, is around $1B. Thus, there is a potential for at least a 3x stock price increase (although small cap biotechs have been known to trade at even higher levels). Eye opening information, eh?
100% of the prescriptions could be off label, and as long as a doctor was the nucleus of each off label prescription, it's fine. Orphan drugs, historically, are readily used off label. Even if AEGR sales staff helped doctors -at their request- with off label use of Juxtapid, that is completely allowed. Yet if AEGR sales reps went beyond their specified promotion regulations, then AEGR should and will pay a fine. Yet it will pay that fine and move on. Long $AEGR